Advanced Search
-
Paradigm Shift in Vaccines: Our Dengue Vaccine Candidate
Laurent Lhopitallier, Sanofi
SanofiParadigm Shift in Vaccines: Our Dengue Vaccine CandidSanofi Pasteur, the vaccines division of Sanofi, has taken an innovative approach to addressing a disease that affects tropical and subtropical countries, without anticipating a return on investment from high-income countries. For the first time, a new vaccine will have its initial introduction in several middle- and low-income countries – where the need is the greatest. more[...]
The Author
-
WHO and Sanofi: A Public-Private Partnership to Save Lives
Dr. Benedict Blayney, Sanofi
Pierre-Guillaume Harscouët, Sanofi
SanofiFor Sanofi, as a global healthcare partner, improving access to healthcare for the most disadvantaged patients is pivotal to its corporate social responsibility approach. At the core of this commitment is the long-term partnership with the World Health Organization (WHO) to control a group of debilitating infectious diseases, called “neglected tropical diseases,” which affect mostly poor people in developing countries. Since the partnership began, in 2001, more than 20 million people in sub-Saharan Africa have been screened for sleeping sickness, and more than 170,000 patients have received free treatment for what is a fatal disease, if left untreated. This partnership has put the elimination of sleeping sickness within reach – a prospect that was unthinkable a decade ago. more[...]
The Author -
Corporate Social Responsibility Reporting 2011
SanofiCorporate Social Responsibility encompasses a broad array of issues. This year, Sanofi's CSR Report addresses 48 topics in it's key areas of Patient, Ethics, People and Planet. Each CSR challenge is important. To avoid a situation where it cannot see the forest for the trees, Sanofi has developed a sound CSR organization and applies sophisticated methods to manage the CSR approach across entire the Group. The CSR approach places the patient at the center of the Group’s business. Woven into the fabric of Sanofi’s values and its strategy, CSR principles provide a vision for the future and foster sustainable growth. more[...]
The Author -
Providing Know-how
Mireille Cayreyre, Sanofi AventisAccessibility and availability of products are as well as the training of good heath care professionals the key problems in rural areas in Africa. We talked about that with Mireille Cayreyre from Sanofi-Aventis. more[...]
The Author
-
Improving the Future of Epileptic Patients
Mireille Cayreyre, Sanofi Aventis
SanofiEpilepsy is not a cause of significant mental impediments. Nevertheless, it is often falsely perceived as a mental disorder in developing countries. Although epilepsy is not fatal, patients who do not receive treatment will experience serious difficulties over their lifetime. In addition to the disease being a handicap in daily life and work, over time, people with epilepsy face social marginalization or even exclusion. In turn, the social group itself is deprived of their economic and social contributions. To address this disease in developing countries, all of these factors need to be taken into account. Sanofi-aventis, as a leader in the global pharmaceutical industry, is thus providing developing countries not only facilitated access to its quality medicines, but also a large number of health services that respond to their specific needs. Epilepsy is not a cause of significant mental impediments. Nevertheless, it is often falsely perceived as a mental disorder in developing countries. Although epilepsy is not fatal, patients who do not receive treatment will experience serious difficulties over their lifetime. In addition to the disease being a handicap in daily life and work, over time, people with epilepsy face social marginalization or even exclusion. In turn, the social group itself is deprived of their economic and social contributions. To address this disease in developing countries, all of these factors need to be taken into account. Sanofi-aventis, as a leader in the global pharmaceutical industry, is thus providing developing countries not only facilitated access to its quality medicines, but also a large number of health services that respond to their specific needs. more[...]
The Author
Partners
|
|
|
|
|
|
|
|
|
|
|
|
Supporters
|
|
|
|
|
|
|
|
|
|
|
|
About Us // Privacy Policy // Copyright Information // Legal Disclaimer // Contact
Copyright © 2012-2018 macondo publishing GmbH. All rights reserved.
The CSR Academy is an independent learning platform of the macondo publishing group.